These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34621112)

  • 1. Molecular docking analysis of Plasmodium falciparum dihydroorotate dehydrogenase towards the design of effective inhibitors.
    Owoloye A; Enejoh OA; Akanbi OM; Bankole OM
    Bioinformation; 2020; 16(9):672-678. PubMed ID: 34621112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances on patents of
    Gehlot P; Vyas VK
    Expert Opin Ther Pat; 2023; 33(9):579-596. PubMed ID: 37942637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicinal chemistry approaches for the discovery of
    Vyas VK; Shukla T; Sharma M
    Future Med Chem; 2023 Jul; 15(14):1295-1321. PubMed ID: 37551689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the Intramolecular Hydrogen Bond on the Active Metabolite Analogs of Leflunomide for Blocking the Plasmodium falciparum Dihydroorotate Dehydrogenase Enzyme: QTAIM, NBO, and Docking Study.
    Heidarian R; Zahedi-Tabrizi M
    Curr Comput Aided Drug Des; 2021; 17(3):480-491. PubMed ID: 32459610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of 3,4-Dihydro-2
    Hartuti ED; Sakura T; Tagod MSO; Yoshida E; Wang X; Mochizuki K; Acharjee R; Matsuo Y; Tokumasu F; Mori M; Waluyo D; Shiomi K; Nozaki T; Hamano S; Shiba T; Kita K; Inaoka DK
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281290
    [No Abstract]   [Full Text] [Related]  

  • 6. Plasmodium falciparum dihydroorotate dehydrogenase: a drug target against malaria.
    Hoelz LV; Calil FA; Nonato MC; Pinheiro LC; Boechat N
    Future Med Chem; 2018 Aug; 10(15):1853-1874. PubMed ID: 30019917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of New Human Malaria Parasite Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors by Pharmacophore and Structure-Based Virtual Screening.
    Pavadai E; El Mazouni F; Wittlin S; de Kock C; Phillips MA; Chibale K
    J Chem Inf Model; 2016 Mar; 56(3):548-62. PubMed ID: 26915022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated structure-guided computational design of novel substituted quinolizin-4-ones as Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors.
    Vyas VK; Shukla T; Tulsian K; Sharma M; Patel S
    Comput Biol Chem; 2022 Dec; 101():107787. PubMed ID: 36401950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QSAR study on the antimalarial activity of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors.
    Hou X; Chen X; Zhang M; Yan A
    SAR QSAR Environ Res; 2016; 27(2):101-24. PubMed ID: 26911561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive review of synthetic strategies and SAR studies for the discovery of PfDHODH inhibitors as antimalarial agents. Part 1: triazolopyrimidine, isoxazolopyrimidine and pyrrole-based (DSM) compounds.
    Sharma M; Pandey V; Poli G; Tuccinardi T; Lolli ML; Vyas VK
    Bioorg Chem; 2024 May; 146():107249. PubMed ID: 38493638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of 7-arylaminopyrazolo[1,5-a]pyrimidines as anti-Plasmodium falciparum, antimalarial, and Pf-dihydroorotate dehydrogenase inhibitors.
    Azeredo LFSP; Coutinho JP; Jabor VAP; Feliciano PR; Nonato MC; Kaiser CR; Menezes CMS; Hammes ASO; Caffarena ER; Hoelz LVB; de Souza NB; Pereira GAN; Cerávolo IP; Krettli AU; Boechat N
    Eur J Med Chem; 2017 Jan; 126():72-83. PubMed ID: 27744189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An exclusive computational insight toward molecular mechanism of MMV007571, a multitarget inhibitor of
    Rawat R; Verma SM
    J Biomol Struct Dyn; 2020 Nov; 38(18):5362-5373. PubMed ID: 31790334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, Design, and Structure⁻Activity Relationship of the Pyrimidone Derivatives as Novel Selective Inhibitors of
    Xu L; Li W; Diao Y; Sun H; Li H; Zhu L; Zhou H; Zhao Z
    Molecules; 2018 May; 23(6):. PubMed ID: 29794978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-Silico molecular docking and simulation studies on novel chalcone and flavone hybrid derivatives with 1, 2, 3-triazole linkage as vital inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
    Thillainayagam M; Malathi K; Ramaiah S
    J Biomol Struct Dyn; 2018 Nov; 36(15):3993-4009. PubMed ID: 29132266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study between 3D-QSAR and Docking-Based Pharmacophore models for potent Plasomodium falciparum dihydroorotate dehydrogenase inhibitors.
    Tseng TS; Lee YC; Hsiao NW; Liu YR; Tsai KC
    Bioorg Med Chem Lett; 2016 Jan; 26(2):265-271. PubMed ID: 26707392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel PfDHODH inhibitors as antimalarial agents via pharmacophore-based virtual screening followed by molecular docking and in vivo antimalarial activity.
    Vyas VK; Qureshi G; Ghate M; Patel H; Dalai S
    SAR QSAR Environ Res; 2016 Jun; 27(6):427-40. PubMed ID: 27310104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coptisine, a natural alkaloid from Coptidis Rhizoma, inhibits plasmodium falciparum dihydroorotate dehydrogenase.
    Lang L; Hu Q; Wang J; Liu Z; Huang J; Lu W; Huang Y
    Chem Biol Drug Des; 2018 Jul; 92(1):1324-1332. PubMed ID: 29582555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.
    Phillips MA; Rathod PK
    Infect Disord Drug Targets; 2010 Jun; 10(3):226-39. PubMed ID: 20334617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing evolutionary fitness in Plasmodium falciparum for drug discovery and suppressing resistance.
    Lukens AK; Ross LS; Heidebrecht R; Javier Gamo F; Lafuente-Monasterio MJ; Booker ML; Hartl DL; Wiegand RC; Wirth DF
    Proc Natl Acad Sci U S A; 2014 Jan; 111(2):799-804. PubMed ID: 24381157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.